Showing results (161-170 of 171) with videos related to

Sort By:
Pageof 18
Bioorganic Chemistry|August 15, 2023
Design, synthesis, and pharmacological evaluation of quinazoline derivatives as novel and potent pan-JAK inhibitorsJinbao Xiang, Yuji Wang, Wanhe Wang, et al.
Frontiers in Public Health|February 6, 2023
Relationships between athletic ability and academic performance in primary school students: A 3-year follow-up studyHao Zong Ji, Cui Jin Bai, Yang Yun, et al.
Behaviour Research and Therapy|November 4, 2024
Effects of brief mindfulness on anxiety-provoked adverse events during ultrasound-guided fine-needle aspiration biopsy of thyroid nodulesLian Zhu, Yan-Hui Xie, Hai-Long Tan, et al.
Fundamental & Clinical Pharmacology|January 22, 2021
Na<sup>+</sup> , K<sup>+</sup> -ATPase participates in the protective mechanism of rat cerebral ischemia-reperfusion through the interaction with glutamate transporter-1Lin-Lin Li, Xue-Ying Ke, Chen Jiang, et al.
Molecular Cancer|August 8, 2019
Correction to: MicroRNA-30d promotes angiogenesis and tumor growth via MYPT1/c-JUN/VEGFA pathway and predicts aggressive outcome in prostate cancerZhuo-Yuan Lin, Guo Chen, Yan-Qiong Zhang, et al.
Cancer Medicine|May 21, 2024
The effect of liver metastases on clinical efficacy of first-line programmed death-1 inhibitor plus chemotherapy in esophageal squamous cell carcinoma: A post hoc analysis of ASTRUM-007 and meta-analysisJing Gao, Yan Song, Xiaoge Kou, et al.
Molecular Cancer|March 1, 2017
MicroRNA-30d promotes angiogenesis and tumor growth via MYPT1/c-JUN/VEGFA pathway and predicts aggressive outcome in prostate cancerZhuo-Yuan Lin, Guo Chen, Yan-Qiong Zhang, et al.
Yi Chuan = Hereditas|February 28, 2020
The 2019 novel coronavirus resourceWen-Ming Zhao, Shu-Hui Song, Mei-Li Chen, et al.
Nature Medicine|February 2, 2023
First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trialYan Song, Bo Zhang, Dao Xin, et al.
Med (New York, N.Y.)|June 13, 2024
First-line serplulimab in metastatic colorectal cancer: Phase 2 results of a randomized, double-blind, phase 2/3 trialZi-Xian Wang, Junjie Peng, Xinjun Liang, et al.
Pageof 18